Dermatofibrosarcoma protuberans(DFSP)is a rare cutaneous intermediate-grade soft tissue tumor characterized by COL1A1::PDGFB fusion in most cases.This fusion drives tumorigenesis and forms the basis for imatinib treat...Dermatofibrosarcoma protuberans(DFSP)is a rare cutaneous intermediate-grade soft tissue tumor characterized by COL1A1::PDGFB fusion in most cases.This fusion drives tumorigenesis and forms the basis for imatinib treatment,which acts by blocking platelet-derived growth factor receptor-beta kinase activity.Apart from this canonical fusion,there is an expanding spectrum of rare fusions,including COL6A3::PDGFD,EMILIN::PDGFD,TNC::PDGFD,etc.,through mole-cular profiling.These atypical rearrangements may be encountered in morpho-logically classic DFSP,unusual anatomic sites,or diagnostically challenging variants such as fibrosarcomatous DFSP.Their recognition is clinically relevant,as they may influence tumor biology,response to targeted therapy,and eligibility for clinical trials.This newly documented DFSP involving the lacrimal sac was initially misdiagnosed as a solitary fibrous tumor,emphasizing the diagnostic pitfalls in anatomically constrained regions and the importance of integrated diagnosis combining histology,immunohistochemistry,and molecular testing.In this editorial commentary,we briefly highlight the ever-growing genomic land-scape of DFSP,report rare fusions and their biological implications,and examine the role of expanded molecular diagnostics in refining diagnosis,guiding therapy,and informing prognosis.Incorporating comprehensive fusion analysis into routine workup may be critical for accurate classification,especially in unusual presentations where reliance on morphology alone risks misdiagnosis.展开更多
目的:探讨隆突性皮肤纤维肉瘤(dermatofibrosarcoma protuberans,DFSP)诊断中免疫表型和荧光原位杂交(fluorescence in situ hybridization,FISH)检测COL1A1/PDGFB融合基因的应用价值。方法:观察73例DFSP中免疫组织化学标记物vimentin、...目的:探讨隆突性皮肤纤维肉瘤(dermatofibrosarcoma protuberans,DFSP)诊断中免疫表型和荧光原位杂交(fluorescence in situ hybridization,FISH)检测COL1A1/PDGFB融合基因的应用价值。方法:观察73例DFSP中免疫组织化学标记物vimentin、CD34、CD99、S100、desmin、SMA和FISH检测COL1A1/PDGFB融合基因的表达。选取85例非DFSP作为免疫组织化学的对照组,10例非DFSP作为FISH检测COL1A1/PDGFB融合基因的对照组。结果:vimentin、CD34、CD99、S100、desmin、SMA在73例DFSP中阳性率分别是100%、91.78%、61.64%、0、0、6.85%,在对照组中不同程度表达,其中CD34的表达在鉴别诊断中有意义。COL1A1/PDGFB融合基因在DFSP的阳性率为86.96%(60/69),对照组均阴性。结论:在DFSP的诊断中,COL1A1/PDGFB融合基因是DFSP较为特异性、敏感性的标记,而CD34是DFSP相对理想的标记。展开更多
目的对一个常染色体显性遗传的Van der Hoeve综合征家系进行详尽的临床表型分析及可能的致病基因COL1A1突变检测,探讨该家系基因型及表型的关系。方法对收集到的Van der Hoeve综合征家系进行病史及血液样本采集,并对家庭主要成员进行COL...目的对一个常染色体显性遗传的Van der Hoeve综合征家系进行详尽的临床表型分析及可能的致病基因COL1A1突变检测,探讨该家系基因型及表型的关系。方法对收集到的Van der Hoeve综合征家系进行病史及血液样本采集,并对家庭主要成员进行COL1A1基因全部外显子DNA序列分析,利用Gene Tool软件及分子生物学网站的信息分析检测数据。结果该家系先证者及其母亲COL1A1基因第40号外显子有两个碱基的缺失(c.2910_2911delAG),导致COL1A1编码的蛋白质的翻译合成在第980位氨基酸提前终止。先证者父亲无此突变。结论该家系先证者及其母亲确定为由c.2910_2911delAG突变导致的Van der Hoeve综合征。与COL1A1基因突变数据库比对,该突变位点未曾报道过。展开更多
文摘Dermatofibrosarcoma protuberans(DFSP)is a rare cutaneous intermediate-grade soft tissue tumor characterized by COL1A1::PDGFB fusion in most cases.This fusion drives tumorigenesis and forms the basis for imatinib treatment,which acts by blocking platelet-derived growth factor receptor-beta kinase activity.Apart from this canonical fusion,there is an expanding spectrum of rare fusions,including COL6A3::PDGFD,EMILIN::PDGFD,TNC::PDGFD,etc.,through mole-cular profiling.These atypical rearrangements may be encountered in morpho-logically classic DFSP,unusual anatomic sites,or diagnostically challenging variants such as fibrosarcomatous DFSP.Their recognition is clinically relevant,as they may influence tumor biology,response to targeted therapy,and eligibility for clinical trials.This newly documented DFSP involving the lacrimal sac was initially misdiagnosed as a solitary fibrous tumor,emphasizing the diagnostic pitfalls in anatomically constrained regions and the importance of integrated diagnosis combining histology,immunohistochemistry,and molecular testing.In this editorial commentary,we briefly highlight the ever-growing genomic land-scape of DFSP,report rare fusions and their biological implications,and examine the role of expanded molecular diagnostics in refining diagnosis,guiding therapy,and informing prognosis.Incorporating comprehensive fusion analysis into routine workup may be critical for accurate classification,especially in unusual presentations where reliance on morphology alone risks misdiagnosis.
文摘目的:探讨隆突性皮肤纤维肉瘤(dermatofibrosarcoma protuberans,DFSP)诊断中免疫表型和荧光原位杂交(fluorescence in situ hybridization,FISH)检测COL1A1/PDGFB融合基因的应用价值。方法:观察73例DFSP中免疫组织化学标记物vimentin、CD34、CD99、S100、desmin、SMA和FISH检测COL1A1/PDGFB融合基因的表达。选取85例非DFSP作为免疫组织化学的对照组,10例非DFSP作为FISH检测COL1A1/PDGFB融合基因的对照组。结果:vimentin、CD34、CD99、S100、desmin、SMA在73例DFSP中阳性率分别是100%、91.78%、61.64%、0、0、6.85%,在对照组中不同程度表达,其中CD34的表达在鉴别诊断中有意义。COL1A1/PDGFB融合基因在DFSP的阳性率为86.96%(60/69),对照组均阴性。结论:在DFSP的诊断中,COL1A1/PDGFB融合基因是DFSP较为特异性、敏感性的标记,而CD34是DFSP相对理想的标记。
文摘目的对一个常染色体显性遗传的Van der Hoeve综合征家系进行详尽的临床表型分析及可能的致病基因COL1A1突变检测,探讨该家系基因型及表型的关系。方法对收集到的Van der Hoeve综合征家系进行病史及血液样本采集,并对家庭主要成员进行COL1A1基因全部外显子DNA序列分析,利用Gene Tool软件及分子生物学网站的信息分析检测数据。结果该家系先证者及其母亲COL1A1基因第40号外显子有两个碱基的缺失(c.2910_2911delAG),导致COL1A1编码的蛋白质的翻译合成在第980位氨基酸提前终止。先证者父亲无此突变。结论该家系先证者及其母亲确定为由c.2910_2911delAG突变导致的Van der Hoeve综合征。与COL1A1基因突变数据库比对,该突变位点未曾报道过。
